New research from an international team of HIV/AIDS experts has reaffirmed the effectiveness of Truvada—the first and only medication approved by the FDA for HIV prevention—expanding our understanding of Truvada’s potency and opening the door to new dosing strategies.
Scientists at the Gladstone Institutes have gotten us one step closer to understanding and overcoming one of the least-understood mechanisms of HIV infection—by devising a method to precisely track the life cycle of individual cells infected with HIV, the virus that causes AIDS.
Warner C. Greene, MD, who directs virology and immunology research at the Gladstone Institutes, has joined with other global AIDS experts to release a locally affordable version of the world’s leading AIDS medical textbook.
Warner C. Greene, MD, PhD, who directs virology and immunology research at the Gladstone Institutes, has been inducted as president of the Association of American Physicians (AAP).
Warner C. Greene, MD, PhD—who directs virology and immunology research at the Gladstone Institutes—has won the 2012 Alumni Achievement Award from the Washington University School of Medicine in St. Louis (WUSTL).
Time magazine has named Gladstone Senior Investigator Robert Grant, MD, MPH, to the 2012 TIME 100, the magazine's annual list of the world's 100 most influential people.
Gladstone Institutes scientist Nevan Krogan, PhD, today is announcing research that identifies how HIV—the virus that causes AIDS—hijacks the body’s own defenses to promote infection. This discovery could one day help curb the spread of the HIV/AIDS pandemic.
Scientists at the Gladstone Institutes have discovered new protein fragments in semen that enhance the ability of HIV, the virus that causes AIDS, to infect new cells—a discovery that one day could help curb the global spread of this deadly pathogen.
A scientist at the Gladstone Institutes has discovered how a gene known as SIRT3 contributes to a suite of health problems sweeping across America, offering new insight into how to combat these potentially fatal conditions.
The Gladstone Institutes will receive funds totaling $5.6 million over five years as part of the first-ever major funding initiative focusing on HIV eradication. The funds will help three principal investigators at Gladstone, an independent biomedical-research organization, to explore the molecular basis for HIV latency where the virus that causes AIDS “hides” dormant within cells waiting for an opportunity to reemerge when therapy is withdrawn.